Sponsor or institution

Clinical trials and research at ADARx Pharmaceuticals, Inc.

• 7Clinical trials
• 27Countries

Newest trials

All recruiting trials (7)

• ADX-038 with or without telitacicept for Chinese adults with IgA nephropathy, C3G, or IC-MPGN

  This Phase 2 trial will test whether ADX-038, given alone or with telitacicept, is safe and helps Chinese adults with biopsy-confirmed IgA nephropathy, complement 3 glomerulopathy, or immune complex MPGN.

  Recruiting at 9 sites Phase 2 ADARx Pharmaceuticals, Inc. · Shenzhen, Guangdong and 8 other locations · NCT07522099

• Long-term treatment with ADX-324 for people with hereditary angioedema

  This extension will try additional doses of ADX-324 (onvuzosiran) to see if continuing the drug is safe and helps people with Type I or II hereditary angioedema who finished the earlier Phase 3 trial.

  Recruiting at 3 sites Phase 3 ADARx Pharmaceuticals, Inc. · Litchfield Park, Arizona and 47 other locations · NCT07428499

• Phase 1 testing of ADX-626 in healthy adults

  This trial will test whether ADX-626 is safe and how the body processes it in healthy adults aged 18 to 45.

  Recruiting Phase 1 ADARx Pharmaceuticals, Inc. · London · NCT07081503

• ADX-038 for geographic atrophy due to age-related macular degeneration

  This phase 2 study will test whether ADX-038 can slow geographic atrophy in people with age-related macular degeneration compared with placebo while monitoring safety and drug levels.

  Recruiting at 40 sites Phase 2 ADARx Pharmaceuticals, Inc. · Gilbert, Arizona and 82 other locations · NCT06990269

• ADX-038 treatment for adults with complement-mediated kidney disease.

  This trial will test whether ADX-038 is safe and helps adults with complement-mediated kidney diseases such as IgA nephropathy, C3G, and IC-MPGN.

  Recruiting at 33 sites Phase 2 ADARx Pharmaceuticals, Inc. · Doral, Florida and 37 other locations · NCT06989359

• STOP-HAE: ADX-324 for hereditary angioedema

  This trial tests whether ADX-324 can reduce HAE attacks in adults with Type 1 or Type 2 hereditary angioedema.

  Recruiting at 52 sites Phase 3 ADARx Pharmaceuticals, Inc. · Litchfield Park, Arizona and 69 other locations · NCT06960213

• Evaluating ADX-038 for safety and effectiveness in healthy individuals and PNH patients

  This study is testing a new drug called ADX-038 to see if it's safe and effective for healthy people and those with paroxysmal nocturnal hemoglobinuria who still have anemia despite treatment.

  Recruiting Phase 1/2 ADARx Pharmaceuticals, Inc. · Brisbane, Queensland and 3 other locations · NCT05876312

Quick answers

How many clinical trials run by ADARx Pharmaceuticals, Inc. are recruiting right now?

7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 27 countries. The most sites are in United Kingdom (6 trials), Australia (5 trials), Spain (4 trials), United States (4 trials), Austria (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 3: 2, Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →